| Pack Size | Single Vial, 10-Pack |
|---|
Semaglutide (a long-acting GLP-1 receptor agonist) is a 31-amino-acid synthetic analogue of native human GLP-1, modified at two backbone positions to extend plasma half-life to roughly one week. Investigators have examined the compound across one of the largest Phase 3 trial programs in the GLP-1 receptor agonist class — the SUSTAIN program in type 2 diabetes, the STEP program in obesity, and the SELECT program in established cardiovascular disease with overweight or obesity. Each batch carries a Janoshik Analytical Certificate of Analysis covering HPLC purity quantification and MS identity confirmation. The minimum-acceptance threshold is 99 percent purity by HPLC. Supplied as a lyophilized powder in a sealed glass vial, 10 mg per vial. Research-grade laboratory compound; human and veterinary use are excluded.
Description
Semaglutide is a 31-residue synthetic peptide modelled closely on native human glucagon-like peptide-1 (GLP-1). Two engineered modifications distinguish the compound from the native molecule. The first is a substitution of α-aminoisobutyric acid (Aib) for alanine at position 8, which prevents cleavage by dipeptidyl peptidase-4 (DPP-4) — the enzyme that ordinarily clips native GLP-1 within minutes of release. The second is a fatty-acid acylation at lysine-26: a C18 diacid attached through a γ-Glu spacer plus two oligoethylene-glycol units. This acyl chain binds reversibly to circulating albumin, slowing renal clearance and pushing plasma half-life to approximately one week.
The combination supports once-weekly subcutaneous dosing in research protocols rather than the multiple-injection-per-day pattern that native GLP-1 would require. An oral formulation also exists; the once-daily oral version uses an absorption-enhancer co-formulation to overcome the very low intrinsic gastrointestinal bioavailability of peptides.
The compound was developed by Novo Nordisk and brought through one of the larger Phase 3 trial programs in metabolic-research history. Researchers have studied the compound across multiple indication contexts. The SUSTAIN program (Phase 3 RCTs in type 2 diabetes) reported glycemic-control outcomes across SUSTAIN 1 through 7 and beyond (PMID 28110911, PMID 29397376, PMID 30615985). The SUSTAIN-6 cardiovascular-outcomes trial in T2D adults with established CVD or high CV risk reported lower rates of major adverse cardiovascular events versus placebo (PMID 27633186). The STEP program at the higher 2.4 mg/week dose tier examined obesity outcomes; STEP 1 reported approximately 14.9 percent mean body weight reduction at 68 weeks (PMID 33567185). The SELECT program extended CV-outcome research into adults with established CVD and overweight or obesity but without T2D, with a 2023 NEJM publication (PMID 37952131) and a 2024 long-term substudy (PMID 38740993).
Ronin Peptides supplies semaglutide as a research-grade lyophilized peptide for laboratory use only. Approved pharmaceutical formulations of the molecule exist under separate distribution channels — three of them, in fact: a once-weekly subcutaneous formulation for type 2 diabetes (approved 2017), an oral formulation for type 2 diabetes (approved 2019), and a higher-dose subcutaneous formulation for chronic weight management (approved 2021). Ronin's research-grade compound is not any of those approved formulations and is not interchangeable with them; the research-grade product is sold strictly for benchwork.
Mechanism in research literature
The receptor target is the GLP-1 receptor — a Gαs-coupled G-protein-coupled receptor expressed across pancreatic islet cells, gastric tissue, hypothalamic appetite-regulating regions, brainstem, and various peripheral tissues. Receptor binding raises intracellular cyclic AMP through adenylyl cyclase activation, triggering downstream signalling that includes glucose-dependent insulin secretion in pancreatic beta cells, glucagon suppression in alpha cells, delayed gastric emptying, and central-nervous-system appetite modulation (PMID 34305810).
Pharmacokinetic engineering enables the compound's long duration of action. Native GLP-1 is cleaved by DPP-4 within minutes and cleared rapidly through renal filtration. The Aib-8 substitution blocks DPP-4 access at the cleavage site, and the C18 acyl chain on lysine-26 binds reversibly to serum albumin, holding the compound in circulation. The combined engineering pushes plasma half-life from approximately two minutes (native GLP-1) to approximately one week (semaglutide).
Investigators have examined the central-nervous-system component of the body-weight effect in detail. A 2020 preclinical study in JCI Insight demonstrated that semaglutide reduced body weight in rodents through distributed neural pathways involving the hypothalamus and brainstem, with effects propagating across multiple appetite-regulating regions rather than acting at a single locus (PMID 32213703). A 2017 clinical study reported reductions in subjective appetite, energy intake, and food preferences, with shifts away from energy-dense foods, in adults with obesity (PMID 28266779).
Researchers have studied the mechanism's reach into cardiovascular outcomes. The SUSTAIN-6 result in T2D and the SELECT result in obesity-without-T2D both documented lower MACE rates with semaglutide versus placebo (PMID 27633186, PMID 37952131). The mechanistic link between GLP-1 receptor agonism and CV-event reduction remains an active research area; proposed contributions include weight reduction, blood-pressure reduction, atherosclerosis-related effects, and direct GLP-1 receptor signalling in vascular tissues.
Studied properties
Type 2 diabetes glycemic control is the original research stream for the compound. The SUSTAIN program documented HbA1c reductions across multiple trial designs. SUSTAIN 1 (monotherapy in drug-naive T2D adults, PMID 28110911) reported HbA1c reductions of approximately 1.4–1.5 percentage points at the 1.0 mg/week dose tier at 30 weeks for the compound. SUSTAIN 7 (active-controlled vs dulaglutide, PMID 29397376) showed the compound was superior on both HbA1c and body weight at matched doses. The pooled SUSTAIN 1–7 analysis (PMID 30615985) integrated efficacy and safety across the program.
The cardiovascular outcomes finding from SUSTAIN-6 (PMID 27633186) — a pre-specified primary CV-outcome analysis in 3,297 T2D adults with established CVD or high CV risk — reported a hazard ratio of 0.74 for the primary composite MACE endpoint versus placebo over a median 2.1-year follow-up. The result established semaglutide as one of the GLP-1 RA class members with demonstrated CV benefit in T2D.
Body weight reduction in adults with overweight or obesity — at the higher 2.4 mg/week dose tier — was documented across the STEP program. The STEP 1 trial in adults with overweight or obesity without T2D (PMID 33567185) reported mean body weight reduction of approximately 14.9 percent at 68 weeks, versus 2.4 percent on placebo. STEP 2 in adults with both T2D and overweight/obesity (PMID 33667417) showed weight reductions of approximately 9.6 percent at 68 weeks. A design overview of STEP trials 1 through 5 (PMID 32441473) describes the program scope.
The SELECT trial (PMID 37952131) evaluated cardiovascular outcomes in adults with established CVD and overweight or obesity but no T2D — a population previously underrepresented in GLP-1 RA CV-outcomes trials. Researchers reported lower rates of major adverse cardiovascular events with semaglutide versus placebo over a median 39.8-month follow-up. A 2024 long-term substudy (PMID 38740993) extended the body-weight findings in this population.
Body composition nuances matter for interpretation of the compound's effects. A 2024 systematic review on lean-mass effects (PMID 38629387) documented that lean mass tends to decrease alongside fat mass during GLP-1 RA therapy, raising research questions about exercise and protein-intake co-interventions in body-composition protocols.
Safety has been characterised across SUSTAIN and STEP programs (PMID 34305810). Gastrointestinal adverse events — nausea, diarrhoea, vomiting — are the most common, occurring most prominently during dose escalation and tending to decline with continued exposure. The Meier 2021 review compares safety profiles across subcutaneous and oral formulations (PMID 34248838).
Compound specifications
| Specification | Value |
|---|---|
| Common name | Semaglutide |
| Schema alternate name | Semaglutide Acetate (chemical-variant designation) |
| Class | Synthetic 31-amino-acid GLP-1 receptor mono-agonist |
| Length | 31 amino acids |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.58 g/mol (free peptide) |
| CAS number | 910463-68-2 |
| PubChem CID | 56843331 |
| Backbone modifications | Aib at position 8 (DPP-4 resistance); γ-Glu-2×OEG-C18 diacid acyl group at Lys-26 (albumin binding) |
| Receptor target | GLP-1 receptor (Gαs-coupled GPCR; pancreas, gastric tissue, hypothalamus, brainstem, peripheral tissues) |
| Plasma half-life | ~1 week (subcutaneous) |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 10 mg peptide, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by Janoshik Analytical) |
Storage and handling
Unopened lyophilized vials hold up well under dry ambient conditions, with usable activity persisting for several weeks even without refrigeration. The unopened original vial is the recommended container until the moment of reconstitution. Refrigeration at 2–8 °C extends practical shelf life into months. Long-term archival storage uses −20 °C in a standard laboratory or household freezer.
Keep vials shielded from light, ideally in their original outer packaging. The fatty-acid acylation introduces an oxidation-sensitive feature, so light protection is more important here than for unmodified peptide chains.
After reconstitution, refrigerate the solution at 2–8 °C without delay. Investigators have measured working potency for a reconstituted preparation at typically four to six weeks under refrigeration — somewhat shorter than the upper end seen with smaller, simpler peptides, since GLP-1 analogues are more thermally sensitive than basic peptide chains.
When a research timeline extends past the working window, common practice is splitting the reconstituted solution into single-use volumes immediately after reconstitution and freezing those aliquots at −20 °C. Researchers have documented that each freeze-thaw cycle damages peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one bulk vial multiple times. Thaw individual aliquots overnight in a refrigerator and use within a few days of thaw.
The reconstitution diluent is USP-grade bacteriostatic water containing 0.9% benzyl alcohol; see the bacteriostatic water product page for reconstitution-grade water.
Compare with similar compounds
| Compound | Class | Documented mechanism (clinical research) | Format at Ronin |
|---|---|---|---|
| Semaglutide | GLP-1 receptor mono-agonist | Single-receptor agonism; pulsatile activation supports glucose-dependent insulin release, glucagon suppression, gastric-emptying delay, central appetite modulation | 10 mg vial |
| Tirzepatide | Dual GLP-1/GIP receptor agonist | Two-receptor agonism; adds GIP-mediated insulin and adipose effects to the GLP-1 baseline | 10 mg vial |
Semaglutide sits at the foundational position in the GLP-1-class research peptide spectrum — a mono-agonist whose effect-size benchmarks anchor the comparison ladder running through Tirzepatide (dual). The Karagiannis 2024 systematic review and network meta-analysis compared subcutaneous Tirzepatide and Semaglutide head-to-head in T2D, finding Tirzepatide produces larger reductions in HbA1c and weight at matched dose tiers (PMID 38613667). the cagrilintide-and-semaglutide combination occupies a different mechanistic neighbourhood, combining GLP-1 agonism with amylin-pathway agonism rather than incrementing GLP-1-class receptor count.
Reconstitution and laboratory handling
A 10 mg semaglutide vial reconstituted with 2 mL of bacteriostatic water yields a working concentration of 5 mg/mL. Alternative dilutions: 1 mL gives 10 mg/mL (concentrated stock); 4 mL gives 2.5 mg/mL (dilute stock).
Reconstitution procedure:
- Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water down the inner wall of the peptide vial as it goes in — never onto the lyophilized cake itself, which would foam and damage peptide structure at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent. If hazy, treat as degraded or contaminated and discard.
For concentration math across different reconstitution volumes, the Ronin peptide reconstitution calculator has semaglutide pre-loaded as a preset.
Frequently asked questions
What is Semaglutide?
Semaglutide is a 31-amino-acid synthetic analogue of native human GLP-1, modified at two positions (Aib at residue 8 and a C18 diacid acylation at lysine-26) to extend plasma half-life to approximately one week. It binds the GLP-1 receptor and engages glucose-dependent insulin secretion, glucagon suppression, gastric-emptying delay, and central appetite modulation. The compound has been studied across the SUSTAIN (T2D), STEP (obesity), and SELECT (CV outcomes in obesity) Phase 3 programs. Ronin Peptides offers semaglutide as a research-grade laboratory reagent; it is sold for bench use only and is not intended for human or veterinary administration.
How does Semaglutide differ from native GLP-1?
Native GLP-1 has a plasma half-life of about two minutes — far too short for practical once-weekly dosing. Semaglutide carries two backbone modifications that together extend half-life to about one week. The Aib substitution at position 8 blocks dipeptidyl peptidase-4 cleavage. The C18 diacid acyl group on lysine-26 binds reversibly to serum albumin, slowing renal clearance. Together these enable once-weekly subcutaneous administration in research protocols that would be impractical with native GLP-1.
What is the regulatory status of Semaglutide?
Semaglutide is a synthetic 31-amino-acid GLP-1 receptor agonist studied for its effects on weight management, glucose regulation, and cardiometabolic health. It is one of the most extensively researched incretin-based peptides with wide clinical use.
Semaglutide is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. It sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics.
Ronin Peptides supplies the compound as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is Semaglutide verified?
Each batch passes through Janoshik Analytical, an independent peptide-analytics lab, for HPLC purity quantification and MS identity confirmation, with the minimum acceptance threshold set at 99 percent purity by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com, so researchers can confirm the certificate's authenticity without trusting the manufacturer's word alone. To pull the COA covering the batch on your order, email support@roninpeptides.ca with your order number; the typical reply turnaround is well under 24 hours.
How is Semaglutide reconstituted?
The standard preparation is 2 mL of bacteriostatic water added to a 10 mg vial, producing a 5 mg/mL solution. Direct the water down the inner wall of the vial as it goes in — never onto the lyophilized cake itself. Swirl gently or invert slowly until fully dissolved. Refrigerate at 2–8 °C immediately after reconstitution. Use the Ronin reconstitution calculator for concentration math across different reconstitution volumes.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch.
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186 | doi:10.1056/NEJMoa1607141
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260. PMID: 28110911 | doi:10.1016/S2213-8587(17)30013-X
- Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. PMID: 28266779 | doi:10.1111/dom.12932
- Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6(4):275-286. PMID: 29397376 | doi:10.1016/S2213-8587(18)30024-X
- Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409-418. PMID: 30615985 | doi:10.1016/j.diabet.2018.12.001
- Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. PMID: 32213703 | doi:10.1172/jci.insight.133429
- Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. PMID: 32441473 | doi:10.1002/oby.22794
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185 | doi:10.1056/NEJMoa2032183
- Davies M et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417 | doi:10.1016/S0140-6736(21)00213-0
- Meier JJ. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Front Endocrinol. 2021;12:645617. PMID: 34248838 | doi:10.3389/fendo.2021.645617
- Smits MM et al. Safety of Semaglutide. Front Endocrinol. 2021;12:645563. PMID: 34305810 | doi:10.3389/fendo.2021.645563
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131 | doi:10.1056/NEJMoa2307563
- Karagiannis T et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2024;67(7):1206-1222. PMID: 38613667 | doi:10.1007/s00125-024-06144-1
- Bikou A et al. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024;25(5):611-619. PMID: 38629387 | doi:10.1080/14656566.2024.2343092
- Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049-2057. PMID: 38740993 | doi:10.1038/s41591-024-02996-7
